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Abstract: Endogenous Cushing’s syndrome is a grave disease that requires a multidisciplinary and individualized treatment approach 
for each patient. Approximately 80% of all patients harbour a corticotroph pituitary adenoma (Cushing’s disease) with excessive secre-
tion of adrenocorticotropin-hormone (ACTH) and, consecutively, cortisol. The goals of treatment include normalization of hormone 
excess, long-term disease control and the reversal of comorbidities caused by the underlying pathology. The treatment of choice is neu-
rosurgical tumour removal of the pituitary adenoma. Second-line treatments include medical therapy, bilateral adrenalectomy and radia-
tion therapy. Drug treatment modalities target at the hypothalamic/pituitary level, the adrenal gland and at the glucocorticoid receptor 
level and are commonly used in patients in whom surgery has failed. Bilateral adrenalectomy is the second-line treatment for persistent 
hypercortisolism that offers immediate control of hypercortisolism. However, this treatment option requires a careful individualized 
evaluation, since it has the disadvantage of permanent hypoadrenalism which requires lifelong glucocorticoid and mineralocorticoid 
replacement therapy and bears the risk of developing Nelson’s syndrome. Although there are some very promising medical therapy 
options it clearly remains a second-line treatment option. However, there are numerous circumstances where medical management of 
CD is indicated. Medical therapy is frequently used in cases with severe hypercortisolism before surgery in order to control the meta-
bolic effects and help reduce the anestesiological risk. Additionally, it can help to bridge the time gap until radiotherapy takes effect. The 
aim of this review is to analyze and present current treatment options in Cushing’s disease.
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Introduction
Endogenous Cushing’s syndrome is a grave and dev-
astating  condition.  Eighty  percent  of  the  patients 
harbour  an  adrenocorticotropin-hormone  (ACTH) 
secreting pituitary adenoma (Cushing’s disease), while 
extrapituitary tumour (ectopic ACTH syndrome) and 
ectopic CRH-secreting tumours are very rare findings. 
The remaining 20% of   ACTH-independent Cushing’s 
syndrome are (in most instances) due to an adrenal 
tumour or, more rarely, macronodular adrenal hyper-
plasia, primary pigmented nodular disease (either as 
isolated disease or as part of the Carney complex), or 
the McCune-Albright syndrome.1,2
In  Cushing’s  disease  (CD),  the  elevated ACTH 
secretion leads to an excess of adrenal gland cortisol 
secretion. The autonomous ACTH-secretion by the 
adenoma and the disturbance of the normal cortisol 
feedback mechanism with the hypothalamo-pituitary-
adrenal (HPA) axis leads to a loss of the circadian 
rhythm  of  cortisol  production,  excessive  cortisol 
production and hypercortisolism. The clinical conse-
quences for the patients are grave and include high 
blood  pressure,  diabetes,  loss  of  libido,  menstrual 
disorders, weight gain, hirsutism, acne, easy bruising, 
purplish skin striae, osteoporosis, muscle weakness, 
depression  and  cognitive  impairment.1,3,4  Although 
externally  visible  clinical  signs  of  the  pathology 
are often strikingly obvious, the rare incidence and 
low prevalence5 of the disease leads to a consider-
able delay between the onset of symptoms and the 
establishment of diagnosis.6,7 One has to consider that 
patients often present with obesity, arterial hyperten-
sion, diabetes mellitus, and depression in the early 
stage of their disease which are wide spread diseases. 
This can hinder the early detection of CD and compli-
cate the diagnosis. On the other hand, untreated CD is 
accompanied by a significantly higher mortality com-
pared to the general population due to vascular and 
metabolic comorbidities so that early disease detec-
tion is of paramount importance.1,5,8–13
The goals of treatment in CD are the normalization 
of cortisol excess, long-term disease control, avoid-
ance of recurrence and reversal of clinical features.14 
The initial therapy of first choice is transsphenoidal 
surgery (TS) for tumour removal. Survival rates of 
patients cured by TS do not differ from those in the 
general population.15,16 In the event of failure after ini-
tial or repeat pituitary surgery, second-line   treatment 
options  include  medical  therapy,  radiotherapy  or 
bilateral adrenalectomy.
To date, the treatment of this complex pathology 
remains  a  challenge.  Only  a  close  interdisciplinary 
treatment concept involving neurosurgeons, endocri-
nologists, oncologists and radiotherapists can guarantee 
a curative treatment result with lasting disease control 
for the patients. In this review, focus is laid on cur-
rent treatment options in Cushing’s disease and old and 
new medical treatment options for CD are analyzed.
surgical Treatment of cD
Transsphenoidal  microsurgical  removal  of  ACTH-
secreting pituitary adenoma is the first-line treatment 
in  CD.14  Although  endoscopic  surgery  has  gained 
increasing recognition as an alternative to the classical 
microscopic technique,17 robust data about outcome 
with this treatment modality are still scarce; a recent 
review of endoscopic surgery showed an overall remis-
sion rate of 74% in CD,18 while the reported overall 
success rates of transsphenoidal microsurgery for CD 
vary from 68.5% to 94%.19–23 Despite an ongoing com-
petitive discussion whether microscopy or endoscopy 
is the superior technique for transsphenoidal surgery, 
one has to keep in mind that the most important deter-
minant of surgical outcome is the experience of the 
neurosurgeon, since both, endoscope and microscope, 
are only visualising devices.
Remission rates, prognostic factors for 
successful surgical treatment and the 
role of preoperative imaging results
A  significant  correlation  between  remission  rates, 
tumour size (with higher remission rates in microade-
nomas) and the degree of invasive growth pattern (ie, 
invasion of the basal dura and/or the cavernous sinus) 
has been shown.19,23–26 In microadenomas, a positive 
MRI finding with a clear visualization of the adenoma 
is  associated  with  remission  rates  between  72.3% 
to 100% of the cases,23,25,27 while remission rates in 
cases with negative or inconclusive MRI drop to only 
64.7%–71.4%.25,28,29 In cases where MRI is negative, 
inferior petrosal sinus sampling (IPSS) offers a fur-
ther diagnostic tool.19,30 However, IPSS is only able 
to predict the correct laterality of a microadenoma 
in 60%–70% of the cases,20,27,31,32 so that it has been 
abandoned by some specialized centres in cases where 
pituitary-dependence of CD has been clearly verified 
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during endocrinological   evaluation.23 Further impor-
tant prognostic factors for successful surgery include 
(i)  histological  confirmation  of    ACTH-secreting 
tumour,  (ii)  low  post-operative    serum-cortisol  lev-
els and (iii) long-lasting adrenal insufficiency after 
surgery.14,15,24,33  In  cases  with  negative  MRI  where 
no adenoma is readily detected during surgery, dif-
ferent  strategies  have  been  applied  ranging  from 
stepwise exploration of the pituitary body21 to total 
hypophysectomy.25
Recent publications by Ikeda et al showed very 
promising  results  in  detecting  early-stage  Cushing 
adenomas by the use of composite methionine-  positron 
emission tomography (MET-PET) and 3.0-tesla MRI. 
The authors investigated a series of 35 patients with 
CD  and  compared  the  detection  rate  of  adenomas 
by the use of superconductive MRI (1.5 or 3.0 tesla) 
and composite images from FDG-PET. They found 
a 100% detection rate (verified by surgical pituitary 
exploration) when using composite MET-PET/3.0-T 
MRI,  while  the  detection  rate  of  FDG-PET/3.0-T 
MR imaging was 73%. Superconductive MRI only 
detected microadenomas in 40% correctly.34
Recurrence rates and success rates  
of re-operation
The overall recurrence rate is 5%–10% at 5 years and 
10%–20% at 10 years. Recurrence occurs more likely 
and  earlier  in  patients  with  macroadenomas  com-
pared to those with microadenomas (mean of 16 vs. 
49 months).26,33 In recurrent CD, repeat transsphenoi-
dal surgery has been shown to be effective in 46% to 
71% of patients.28,35–40 Because of significant scar tissue 
and altered normal anatomy, repeat surgery for recur-
rent pituitary adenomas is in general more challenging 
than an initial operation or an immediate re-operation 
for persistent disease. Ikeda et al (2011) found that the 
use of MET-PET was extremely helpful in the detec-
tion of adenoma in recurrent CD in one 45 year old 
female patient.41 Surgical navigation and the Doppler 
probe are highly recommended for localizing the por-
tion of the internal carotid artery (ICA) within the cav-
ernous sinus and for confirming regional anatomy.39,42
Complications of surgery
The most common surgical complications of trans-
sphenoidal surgery include diabetes insipidus, cere-
brospinal fluid (CSF) leakage, vascular complications 
(occlusion and bleeding), and hypopituitarism. The 
reported rate of permanent diabetes insipidus ranges 
from 1% to 6%,15,16,20,27,43 while the rate of hypopituitar-
ism (other than the desired adrenal insufficiency) lies 
between 8.7% to 53% in different series.15,16,20,25,27,43 
Hypopituitarism is clearly correlated with the extent 
of surgery, more radical procedures yielding higher 
complication  rates14,15,24  and  a  higher  rate  of  post-
operative  hypopituitarism.15,25  Also,  repeat  surgery 
is associated with a higher rate of CSF leakage and 
hypopituitarism.44,45
Radiotherapy
In cases with persistent or recurrent disease where 
operative  treatment  options  have  been  exhausted 
(eg, due to tumour invasion of the cavernous sinus), 
radiotherapy is a well-established second-line   therapy. 
  Radiotherapy  is  either  performed  as  fractionated 
external  beam  radiotherapy  or  stereotactic  surgery 
(SR). Fractionated radiotherapy is indicated for ade-
nomas with proximity to the optic pathways and with 
large volume. SR is used for small adenoma volumes. 
  Circumscribed residual adenomas within the cavern-
ous sinus are particularly suitable for SR. For fraction-
ated radiotherapy, the remission rates in the literature 
are heterogeneous and range from 10% to 83%. In 
larger series of SR, remission rates are about 50%.46–49 
  Typical radiation doses in conventional radiotherapy 
range from 45 to 54 Gray (Gy).50 SR is usually per-
formed as a single fraction dose. Margin doses reported 
in the literature usually range from 15–32 Gy.51
The main disadvantage of both radiotherapeutic 
procedures is the delayed response to treatment. For 
both procedures the mean reported time to remission 
interval is 3 years after treatment,47,48,52–55 and effective 
anti-secretory drugs should be used until the response 
becomes  evident.  Hypopituitarism  is  the  most  fre-
quent side effect of radiotherapy in ACTH-secreting 
adenomas and occurs in over 50% of the cases after 
fractionated radiotherapy47,54,56,57 and up to 66% after 
SR.50 Additionally, radiotherapy may cause damage to 
the brain and the cranial nerves, especially the optic 
apparatus.46 The risk for second tumour formation is 
considered to be in the range of 1%–2% with conven-
tional radiotherapy.54 Studies providing longer follow 
up data after SR are still necessary. However, reports 
about the development of cranial nerve deficits and 
deterioration of visual acuity to complete loss after a 
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second treatment with SR clearly suggest caution for 
the repetitive use of SR.48,58 After an initial response 
to both types of radiotherapy, relapse may still occur, 
so that long-term follow up is necessary.50,59
Bilateral Adrenalectomy
Bilateral adrenalectomy is the second-line treatment 
for  persistent  hypercortisolism  that  offers  immedi-
ate control of hypercortisolism. The morbidity of the 
operative procedure itself can be minimized by the 
use of endoscopic approaches. However, this treat-
ment option requires a careful individualized evalu-
ation and is generally only indicated in (i) patients 
with persistence of hypercortisolism despite medical 
therapy, (ii) intolerance to medical therapy, (iii) as an 
alternative to long-term medical treatment after failed 
pituitary radiotherapy or (iv) younger women who 
wish to maintain fertility.12,14
This treatment option clearly has the disadvantage 
of permanent hypoadrenalism that necessitates a life-
long  glucocorticoid  and  mineralocorticoid  replace-
ment  therapy.60  Additionally,  it  bears  the  risk  of 
developing Nelson’s syndrome, so that a close endo-
crinological  follow-up  with ACTH  evaluation  and 
regular MRI scans are mandatory in all adrenalecto-
mized patients.60,61
Medical Therapy
Although there are some very promising prospects due 
to the development of new drugs that have recently given 
medical treatment in CD significant space, it clearly 
remains a second-line treatment option.   However, there 
are numerous circumstances where medical manage-
ment of CD is indicated. Medical therapy is frequently 
used in cases with severe hypercortisolism before sur-
gery in order to control the metabolic effects and help 
reduce the anestesiological risk.62 Moreover, medical 
treatment plays a pivotal role in patients waiting for 
the full effect of pituitary radiotherapy and is often 
essential for patients where surgery has failed to con-
trol CD, since it helps reducing or normalizing hyper-
cortisolemia. It has been claimed that medical therapy 
should always be performed before considering bilat-
eral adrenalectomy.12 However, early bilateral adrena-
lectomy should be considered after surgical failure in 
patients who are threatened by severe comorbidities 
because of uncertain control of Cushing’s disease with 
medical treatment and delayed control by RT.
Furthermore, in the rare cases of CD patients with 
metastatic disease (although far more common in cor-
tisol secreting adrenal cancer), medical therapy is a 
helpful palliative treatment modality.14
Medical therapeutic agents for treatment of CD 
can be divided into two categories: adrenal enzyme 
inhibitors and neuromodulatory agents.
Adrenal enzyme Inhibitors
Ketoconazole
Usually, ketoconazole is widely used in the medi-
cal treatment of CD. Ketoconazole is an imidazole 
derivative and was initially developed as an oral anti-
fungal drug. It inhibits sex-steroid synthesis by its 
action on C17–20 lyase61 and cortisol synthesis by 
preventing cholesterol side chain cleavage (inhibiting 
17a-hydroxylase and 18a-hydroxylase activity).64,65 
Treatment usually starts with a dose of 200 mg twice 
daily and may be increased until 1200 mg daily given 
in four doses.66–68 The adjustment of doses is based on 
the 24-hour urine free cortisol (UFC) levels.62
Efficacy
In a metaanalysis of eight trials with daily ketocon-
azole doses ranging from 400 to 1200 mg, an average 
normalization of UFC levels was found in up to 93% 
of patients who took their medication consequently 
without interruption.69
Side effects
The  most  common  side  effect  is  hepatic  dysfunc-
tion with elevated levels of serum transaminases.69 
  Hepatotoxicity  is  dose-dependent  and  reversible 
when  the  drug  is  discontinued.  Other  side  effects 
include  nausea,  vomiting,  skin  rash,  and  loss  of 
libido and potence in males due to decreased sex-
steroid    synthesis.  This  drug  is  contraindicated  in 
pregnant  females  due  to  teratogenicity.12  Ketocon-
azole is a potent cytochrome P450 enzyme inhibi-
tor, and has interactions with the following drugs: 
benzodiazepines aside from lorazepam; a variety of 
calcium channel blockers such as nifedipine and vera-
pamil; 3-hydroxy-3-methyl-glutaryl- CoA reductase 
inhibitors,  aside  from  pravastatin  and  fluvastatin; 
phenytoin; warfarin; and theophylline. Histamine-2-
receptor blockers and proton pump inhibitors should 
be avoided during treatment with ketoconazole as its 
absorption depends on gastric acidity.60 Ketoconazole 
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is  usually  used  in  combination  with  other  adrenal 
enzyme inhibiting drugs in order to minimize side 
effects of high drug doses. The second reason is that 
high doses of ketoconazole lead to increased ACTH 
levels that overwhelm the drug’s inhibitory effects.62
Metyrapone
Metyrapone  is  another  drug  that  can  be  used  as 
an  adjunctive  treatment  for  Cushing  disease.70  It 
blocks the production of cortisol by inhibiting 11β-
hydroxylase production of cortisol from deoxycortisol 
in the adrenal gland. The resultant relative decrease of 
cortisol may stimulate further ACTH secretion as an 
aftermath, increasing adrenal androgen and aldoster-
one precursors with weak mineralocorticoid   activity. 
Metyrapone is usually started in a dose of 250 mg 
three times daily and can be titrated up to a maximum 
of 6 g per day.
Efficacy
Metyrapone  has  shown  efficacy  over  an  extended 
period of treatment.62,71 In a large series of 53 CD 
patients,  short-term  mean  serum  cortisol  levels 
of #400 nmoL/L were obtained in 75% of patients 
and effective long-term effects were observed in 83% 
of the 24 patients who received the drug after pituitary 
irradiation (mean 2250 mg/day, median 27 months).72 
In severe cases of CD, a block-and-replace scheme can 
be used for immediate reversal of hypercortisolism.
Side effects
The mean side effects are hirsutism, acne, gastroin-
testinal upset and dizziness. Hypertension, edema or 
hypokalemia due to raised mineralocorticoid effects 
are  rare,  but  may  require  the  discontinuation  of 
therapy.63
Aminoglutethimide
Aminoglutethimide  prevents  conversion  of  choles-
terol to pregnenolone, thus inhibiting not only corti-
sol but also estrogen and aldosterone production. The 
usual dose given is 250 mg twice or thrice daily.
Efficacy
Aminoglutethimide seems to be less efficient in CD 
compared to other causes of CS67,69 and is most often 
used as an adjunct to metyrapone for reducing doses 
and the drug toxicity.
Side effects
The primary side effect is a generalized,   self-limited 
pruritic  rash  that  is  usually  manageable  with 
  antihistamines  without  requiring  drug  cessation. 
Other side effects include dizziness, blurred vision, 
and, as the drug blocks thyroid hormone synthesis, 
hypothyroidism. Cholestasis and bone marrow sup-
pression are very rare side effects.   Aminoglutethimide 
is a cytochrome P450 enzyme inducer and may have 
several  potential  interactions  with  other  medica-
tions,   including the decrease of ketoconazole levels. 
  Additionally, it increases the metabolism of dexame-
thasone but not of hydrocortisone, so that the latter is 
often used in patients requiring steroid replacement 
therapy.73,74
Mitotane
Mitotane  inhibits  several  steps  in  glucocorticoid 
synthesis  through  inhibition  of  11a-hydroxylase, 
18-hydroxylase,  3a-hydroxylase,  hydroxysteroid 
dehydrogenase  and  several  cholesterol  side  chain 
cleavage enzymes.73,74 Today, its primary use is in 
patients with adrenocortical carcinoma, since doses 
greater than 4 g per day have an adrenolytic action 
in  adrenal  cortical  cell  mitochondria  and  lead  to 
carcinoma cell destruction and cellular necrosis.62,77 
  Mitotane is often started at 250 to 500 mg nightly 
with slow escalation of the dose to 4 to 12 g/day.
Efficacy
In a large historical study with 46 CD patients receiv-
ing 4 to 12 g of Mitotane per day, a remission rate of 
83% was observed within 8 months after initiation 
of treatment.78 Sixteen patients received a combina-
tion of mitotane and radiotherapy and disease con-
trol was achieved in all of them. Another study with 
a lower-dose mitotane regime (up to 4 g/day) in order 
to reduce side effects showed remission in 29 of 36 
patients (81%) with adjunctive radiotherapy.79 In 17 
of these patients, no long-term mitotane therapy was 
necessary, pointing to a persistent adrenolytic effect 
after  the  drug  is  stopped.  Monitoring  of  morning 
serum cortisol is performed after starting mitotane 
treatment, and once a decline is observed, predni-
sone  or  dexamethasone  replacement  therapy  can 
begin as needed. Usually, the use of prednisone is 
more favorable since its metabolism is not increased 
by mitotane.80
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Side effects
The severe side effects of mitotane limit its use in 
CD and have essentially set it as second or third line 
medication after ketoconazole.62 The most commonly 
documented drug-related side effects are nausea and 
hypercholesterolemia.78 At higher doses, neurological 
side effects are common, including gait ataxia, vertigo, 
confusion,  and  word  finding  difficulties.76  Patients 
receiving mitotane therapy without radiotherapy are 
at risk to develop Nelson syndrome. Finally, the drug 
is teratogenic and therefore contraindicated in preg-
nant women.81
etomidate
Etomidate,  a  commonly  used  short-acting  intrave-
nous anesthestic, is an exceedingly potent inhibitor 
of 11β-hydroxylase as well as an inhibitor of 17a-
hydroxylase.63 It is mainly reserved for acute control 
of hypercortisolemia due to its sedative effects and 
sole availability in intravenous form.62 Although in 
one study in which the authors used it at a dose of 
0.3 mg/kg/hour with a normalization of serum corti-
sol levels within 12 hours in six patients with CD, its 
use in daily practice remains limited.82
neuromodulatory Agents
To  date,  the  search  for  more  “specific”  drugs  that 
may act on ACTH secretion at the pituitary adenoma 
level without interfering with other hormone synthe-
sis and with less severe side effects that may allow 
for primary treatment is still ongoing. Some prom-
ising agents involve somatostatin analogs and dop-
amine agonists which already play an important role 
in the treatment of acromegaly83 and prolactinomas.12 
Although the results in CD are still mainly experi-
mental with few clinical results, it is worth while to 
dedicate a section of this review to neuromodulatory 
active agents.
Somatostatin (SS) analogs
Preclinical studies in cultured rat pituitary corticotro-
phs show expression of multiple somatostation recep-
tors (SST), including subtype 2 (sst2) and subtype 
5 (sst5).84
Two studies85,86 investigated the effects of SS ana-
logs in human corticotroph adenoma tissues: a superior 
ACTH inhibition by pasireotide as compared to oct-
reotide85 and a dissociation between the anti-secretory 
and  anti-proliferative  effects  of  pasireotide  were 
observed.86
In clinical studies the use of the currently available 
somatostatin analogs octreotide and lanreotide were, 
other than in acromegaly,83 mostly ineffective in CD. 
However, more promising results have been reported 
with  the  new  somatostatin  analogue    pasireotide.3 
Pasireotide  has  a  high  affinity  to  sst5  which  pre-
dominates  in  corticotroph  adenomas.14  A  recently 
published  phase  II,  proof-of-concept,  open-label, 
single arm, multicenter study of pasireotide enrolled 
39 CD patients from 10 centers.3 Study participants 
self-  administered  pasireotide  600  µg  twice  a  day 
for 15 days at 0900 and 2100 h. Ten patients did not 
respond  to  the  treatment,  76%  of  the  participants 
showed  a  decrease  of  urinary  free  cortisol  (UFC) 
levels, but only five of them (17%) had normalized 
UFC levels after 15 days. The mean UFC levels in 
the overall cohort decreased from baseline by 44.5%. 
Additionally, a trend toward a lower baseline UFC 
level as predictive factor for a response to pasireotide 
(P = 0.102) was observed, while no significant differ-
ences between ACTH values between responders and 
non-responders were observed. The most observed 
side effects of the medication were gastrointestinal 
disorders  (54%),  diarrhea  (44%),  abdominal  pain 
(18%), nausea (23%) and hyperglycemia (36%).
Dopamine agonists
In humans, no conclusive data exist as to whether or 
not dopamine agonist receptors (DA) have an imme-
diate regulatory effect on ACTH release in normal 
corticotroph cells.87 In this context, the intermediate 
lobe (despite being a rudimentary structure) seems to 
play a significant role, since it maintains important 
biological functions: corticotroph adenomas arising 
from there are more likely to respond to DA treat-
ment with the classical substance bromocriptin.88 The 
results of a 24-month treatment with cabergoline in 
20 CD patients was recently presented: a maintained 
control of cortisol excess was found in 40% and an 
induced tumor shrinkage in 20% of patients, treat-
ment doses varying between 1 and 7 mg   cabergoline/
week.89  While  the  authors  did  not  report  any  sig-
nificant  side  effects  of  the  therapy  in  their  study 
population  (with  the  exception  of  2  patients  who 
developed hypotension associated with severe asthe-
nia that forced them to discontinue the medication), 
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it is noteworthy that the drug has been reported to 
be responsible for an increased prevalence of cardiac 
valve insufficiency12 in patients with long-term cab-
ergoline therapy.
Combined treatment with SS analogs 
and DA agonists
Since  both,  SST  and  DA  receptors  are  present  in 
human corticotroph adenomas, a combination ther-
apy of both substances appears to be a further rea-
sonable treatment approach that is currently object to 
clinical trials. A very recent study enrolling 17 CD 
patients achieved a sustained normalization of UFC 
levels in 5 patients (29%) with a pasireotide mono-
therapy. The addition of cabergoline led to a normal-
ization of UFC in further 4 patients (24%). At day 60 
of treatment, 9 patients (53%) had normalized UFC 
levels, while all but one of the remaining 8 patients 
with persistently high UFC levels showed a tendency 
toward  normalization  (mean  decrease  of  the  UFC 
level 48% ± 6%).90
Glucocorticoid receptor antagonist
Mifepristone (known as RU486) is the latest com-
petitive antagonist to glucocorticoids that was engi-
neered to block the peripheral effects of glucorticoids. 
  Similar to the GH peripheral antagonist pegvisomant 
that is successfully used in acromegaly91 its efficacy 
can be judged by its medical response but not by lev-
els of ACTH or cortisol. Currently, there is no sig-
nificant clinical experience reported yet with its use 
in treatment of CD. Side effects are hyperpigmen-
tation,  hypertension,  hypokalemia,  psychosis,  and 
cardiomypathy.62
Other neuromodulatory Agents
These  include  retinoic  acid  and  peroxisome 
  proliferator-activated  receptor-γ  PPAR-γ  (rosiglita-
zone).   Retinoic acid showed an in vitro antiprolif-
erative action as well as ACTH and corticosterone 
  inhibition. In vivo these effects were confirmed in 
mice with experimental ACTH secreting tumors as 
well as in dogs with CD. While the efficacy of retin-
oic acid in humans still needs to be tested in clini-
cal trials, the clinical trials with rosiglitazone led to 
disappointing  results.  One  study  including  14  CD 
patients (7 with unsuccessful surgery, 7 yet untreated) 
showed  a  s  ignificantly  lowered  24  hour  UFC  in 
6 patients with a dose varying between 8–16 mg of 
rosiglitazone for 1–7 months.92 Another study enroll-
ing 10 patients (4 untreated yet, 4 with relapse after 
surgery, 2 after failed surgery) did not find any signif-
icant reduction of 24 hour UFC after a median treat-
ment of 3 months (range 1–8 months) with a dose 
of 4–16 mg   rosiglitazone.93 The reported side effects 
included  weight  increase,  edema,  somnolence  and 
hirsutism. While rosiglitazone was used in most stud-
ies, the results of one study with   pioglitazone showed 
similar unencouraging results: 5 patients received a 
treatment of 45 mg for 30 days, with no lowering of 
24 hour UFC in any study participant.
Alkylating agents in aggressive AcTH 
producing adenomas/carcinomas
Temozolomide,  an  orally  administered  alkylating 
agent, has recently demonstrated to have a significant 
activity against aggressive pituitary tumours resistant 
to multimodality therapy. These tumours are associ-
ated  with  substantial  morbidity  and  mortality.94–97 
There is strong evidence that low O6-  methylguanine-
DNA-methyltransferase (MGMT) immunoexpression 
correlates with response to temozolomide chemother-
apy,94,97 since MGMT is a DNA repair enzyme that 
removes  alkylating  adducts  induced  by  temozolo-
mide and counteracts its effects. A very recent review 
article evaluating the response rates in 40 reported 
pituitary tumour cases described an overall response 
rate of 60%. The best response rates were observed 
in prolactinomas (73%) as well as in ACTH-secret-
ing tumours (60%), while   non-functioning adenomas 
showed lower response rates (76%).96
conclusions
CD is a very severe condition that requires early detec-
tion as well as rapid curative treatment and effective 
disease control in order to avoid long-term sequelae 
of the disease. The first treatment of choice is the neu-
rosurgical tumor removal, most cases being operated 
via a transsphenoidal approach. In cases where the sur-
gical procedure alone cannot achieve disease control, 
second-line treatment options have to be considered. 
These consist of medical therapy, radiotherapy and 
bilateral adrenalectomy. Treatment results with soma-
tostatin-analogues directed to the receptor subtype 5 
are promising and might offer an option for long-
term medical therapy. SR radiotherapy is increasingly 
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used for circumscribed residual adenomas within the 
cavernous sinus. Therefore, the search for new and 
effective medical tools is still open. All these aspects 
emphasize the need of effective treatment of CD itself 
as well as long-term follow-up of these patients in 
order to control its complications and detect recur-
rence in a timely fashion.
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